Brought to you by 
Merck and Roche form hepatitis C collaboration
10 Apr 2020
Executive Summary
Roche’s Genentech Inc. has agreed to nonexclusively co-promote in the US Merck & Co. Inc.’s newly approved Victrelis (boceprevir) along with peginterferon alfa and ribavirin as a triple therapy for chronic hepatitis C. Presently the standard HCV regimen includes coupling the interferon with ribavirin.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com